nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—ABCG2—Teniposide—lymphatic system cancer	0.125	0.181	CbGbCtD
Gefitinib—ABCG2—Mitoxantrone—lymphatic system cancer	0.0871	0.126	CbGbCtD
Gefitinib—CYP3A5—Teniposide—lymphatic system cancer	0.069	0.1	CbGbCtD
Gefitinib—ABCG2—Vincristine—lymphatic system cancer	0.0599	0.087	CbGbCtD
Gefitinib—CYP2C19—Teniposide—lymphatic system cancer	0.0557	0.0808	CbGbCtD
Gefitinib—CYP2C9—Teniposide—lymphatic system cancer	0.0463	0.0671	CbGbCtD
Gefitinib—ABCG2—Methotrexate—lymphatic system cancer	0.0363	0.0527	CbGbCtD
Gefitinib—CYP3A5—Vincristine—lymphatic system cancer	0.0332	0.0482	CbGbCtD
Gefitinib—ABCB1—Mitoxantrone—lymphatic system cancer	0.0314	0.0456	CbGbCtD
Gefitinib—CYP3A4—Cytarabine—lymphatic system cancer	0.0273	0.0396	CbGbCtD
Gefitinib—CYP3A4—Teniposide—lymphatic system cancer	0.0269	0.039	CbGbCtD
Gefitinib—ALB—Methotrexate—lymphatic system cancer	0.025	0.0363	CbGbCtD
Gefitinib—ABCB1—Vincristine—lymphatic system cancer	0.0216	0.0314	CbGbCtD
Gefitinib—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0188	0.0273	CbGbCtD
Gefitinib—ABCB1—Methotrexate—lymphatic system cancer	0.0131	0.019	CbGbCtD
Gefitinib—CYP3A4—Vincristine—lymphatic system cancer	0.0129	0.0188	CbGbCtD
Gefitinib—Bosutinib—ALK—lymphatic system cancer	0.00869	1	CrCbGaD
Gefitinib—ERBB3—Podofilox—Teniposide—lymphatic system cancer	0.00289	0.294	CbGdCrCtD
Gefitinib—CHEK2—Podofilox—Teniposide—lymphatic system cancer	0.00195	0.199	CbGdCrCtD
Gefitinib—CHEK2—Vindesine—Vincristine—lymphatic system cancer	0.00184	0.187	CbGdCrCtD
Gefitinib—ERBB3—Vinblastine—Vincristine—lymphatic system cancer	0.00118	0.12	CbGdCrCtD
Gefitinib—CHEK2—Vinorelbine—Vincristine—lymphatic system cancer	0.00116	0.118	CbGdCrCtD
Gefitinib—Haemorrhage—Fludarabine—lymphatic system cancer	0.00107	0.00366	CcSEcCtD
Gefitinib—Hepatic failure—Vincristine—lymphatic system cancer	0.00105	0.00359	CcSEcCtD
Gefitinib—Febrile neutropenia—Methotrexate—lymphatic system cancer	0.00105	0.00359	CcSEcCtD
Gefitinib—Eruption—Methotrexate—lymphatic system cancer	0.00103	0.00351	CcSEcCtD
Gefitinib—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00102	0.00349	CcSEcCtD
Gefitinib—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00101	0.00346	CcSEcCtD
Gefitinib—Hypoxia—Methotrexate—lymphatic system cancer	0.000994	0.0034	CcSEcCtD
Gefitinib—Anaemia—Teniposide—lymphatic system cancer	0.000979	0.00335	CcSEcCtD
Gefitinib—Nail disorder—Methotrexate—lymphatic system cancer	0.000973	0.00333	CcSEcCtD
Gefitinib—Arrhythmia—Fludarabine—lymphatic system cancer	0.000955	0.00327	CcSEcCtD
Gefitinib—Alopecia—Fludarabine—lymphatic system cancer	0.000945	0.00323	CcSEcCtD
Gefitinib—Malnutrition—Fludarabine—lymphatic system cancer	0.000931	0.00318	CcSEcCtD
Gefitinib—Hypokalaemia—Carmustine—lymphatic system cancer	0.0009	0.00308	CcSEcCtD
Gefitinib—Interstitial lung disease—Methotrexate—lymphatic system cancer	0.000892	0.00305	CcSEcCtD
Gefitinib—Weight decreased—Bleomycin—lymphatic system cancer	0.000886	0.00303	CcSEcCtD
Gefitinib—Pneumonia—Bleomycin—lymphatic system cancer	0.000878	0.003	CcSEcCtD
Gefitinib—Dehydration—Vincristine—lymphatic system cancer	0.000878	0.003	CcSEcCtD
Gefitinib—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.000864	0.00295	CcSEcCtD
Gefitinib—Anaemia—Fludarabine—lymphatic system cancer	0.00086	0.00294	CcSEcCtD
Gefitinib—Infection—Teniposide—lymphatic system cancer	0.000859	0.00294	CcSEcCtD
Gefitinib—Dehydration—Mitoxantrone—lymphatic system cancer	0.000855	0.00293	CcSEcCtD
Gefitinib—Stomatitis—Bleomycin—lymphatic system cancer	0.000851	0.00291	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00085	0.00291	CcSEcCtD
Gefitinib—Thrombocytopenia—Teniposide—lymphatic system cancer	0.000846	0.00289	CcSEcCtD
Gefitinib—Malaise—Fludarabine—lymphatic system cancer	0.000839	0.00287	CcSEcCtD
Gefitinib—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.000837	0.00286	CcSEcCtD
Gefitinib—Haematuria—Bleomycin—lymphatic system cancer	0.000833	0.00285	CcSEcCtD
Gefitinib—Pruritus—Mechlorethamine—lymphatic system cancer	0.000829	0.00284	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.000828	0.00283	CcSEcCtD
Gefitinib—Pleural effusion—Methotrexate—lymphatic system cancer	0.000824	0.00282	CcSEcCtD
Gefitinib—Anorexia—Teniposide—lymphatic system cancer	0.000824	0.00282	CcSEcCtD
Gefitinib—Cough—Fludarabine—lymphatic system cancer	0.000812	0.00278	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.000811	0.00277	CcSEcCtD
Gefitinib—Hypotension—Teniposide—lymphatic system cancer	0.000808	0.00276	CcSEcCtD
Gefitinib—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000802	0.00274	CcSEcCtD
Gefitinib—CHEK2—Vinblastine—Vincristine—lymphatic system cancer	0.000799	0.0813	CbGdCrCtD
Gefitinib—Haemoglobin—Bleomycin—lymphatic system cancer	0.000788	0.0027	CcSEcCtD
Gefitinib—Haemorrhage—Bleomycin—lymphatic system cancer	0.000784	0.00268	CcSEcCtD
Gefitinib—Dyspnoea—Teniposide—lymphatic system cancer	0.000771	0.00264	CcSEcCtD
Gefitinib—Pneumonia—Carmustine—lymphatic system cancer	0.000767	0.00262	CcSEcCtD
Gefitinib—Infection—Fludarabine—lymphatic system cancer	0.000755	0.00258	CcSEcCtD
Gefitinib—Decreased appetite—Teniposide—lymphatic system cancer	0.000751	0.00257	CcSEcCtD
Gefitinib—Vomiting—Mechlorethamine—lymphatic system cancer	0.000745	0.00255	CcSEcCtD
Gefitinib—Nervous system disorder—Fludarabine—lymphatic system cancer	0.000745	0.00255	CcSEcCtD
Gefitinib—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000744	0.00254	CcSEcCtD
Gefitinib—Stomatitis—Carmustine—lymphatic system cancer	0.000743	0.00254	CcSEcCtD
Gefitinib—Rash—Mechlorethamine—lymphatic system cancer	0.000739	0.00253	CcSEcCtD
Gefitinib—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000739	0.00253	CcSEcCtD
Gefitinib—Weight decreased—Vincristine—lymphatic system cancer	0.000738	0.00253	CcSEcCtD
Gefitinib—Pneumonia—Vincristine—lymphatic system cancer	0.000732	0.0025	CcSEcCtD
Gefitinib—Anorexia—Fludarabine—lymphatic system cancer	0.000724	0.00248	CcSEcCtD
Gefitinib—Weight decreased—Mitoxantrone—lymphatic system cancer	0.000719	0.00246	CcSEcCtD
Gefitinib—Proteinuria—Methotrexate—lymphatic system cancer	0.000718	0.00246	CcSEcCtD
Gefitinib—Pneumonia—Mitoxantrone—lymphatic system cancer	0.000713	0.00244	CcSEcCtD
Gefitinib—Stomatitis—Vincristine—lymphatic system cancer	0.000709	0.00243	CcSEcCtD
Gefitinib—Protein urine present—Methotrexate—lymphatic system cancer	0.000708	0.00242	CcSEcCtD
Gefitinib—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000707	0.00242	CcSEcCtD
Gefitinib—Nausea—Mechlorethamine—lymphatic system cancer	0.000696	0.00238	CcSEcCtD
Gefitinib—Alopecia—Bleomycin—lymphatic system cancer	0.000693	0.00237	CcSEcCtD
Gefitinib—Stomatitis—Mitoxantrone—lymphatic system cancer	0.000691	0.00236	CcSEcCtD
Gefitinib—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.000689	0.00236	CcSEcCtD
Gefitinib—Haemoglobin—Carmustine—lymphatic system cancer	0.000688	0.00235	CcSEcCtD
Gefitinib—Urticaria—Teniposide—lymphatic system cancer	0.000687	0.00235	CcSEcCtD
Gefitinib—Haemorrhage—Carmustine—lymphatic system cancer	0.000684	0.00234	CcSEcCtD
Gefitinib—Abdominal pain—Teniposide—lymphatic system cancer	0.000683	0.00234	CcSEcCtD
Gefitinib—Body temperature increased—Teniposide—lymphatic system cancer	0.000683	0.00234	CcSEcCtD
Gefitinib—Dyspnoea—Fludarabine—lymphatic system cancer	0.000677	0.00232	CcSEcCtD
Gefitinib—Haematuria—Mitoxantrone—lymphatic system cancer	0.000676	0.00231	CcSEcCtD
Gefitinib—Oedema peripheral—Carmustine—lymphatic system cancer	0.000674	0.00231	CcSEcCtD
Gefitinib—Ulcer—Methotrexate—lymphatic system cancer	0.000667	0.00228	CcSEcCtD
Gefitinib—Decreased appetite—Fludarabine—lymphatic system cancer	0.00066	0.00226	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000656	0.00224	CcSEcCtD
Gefitinib—Fatigue—Fludarabine—lymphatic system cancer	0.000655	0.00224	CcSEcCtD
Gefitinib—Constipation—Fludarabine—lymphatic system cancer	0.00065	0.00222	CcSEcCtD
Gefitinib—Pain—Fludarabine—lymphatic system cancer	0.00065	0.00222	CcSEcCtD
Gefitinib—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000645	0.00221	CcSEcCtD
Gefitinib—Respiratory failure—Methotrexate—lymphatic system cancer	0.000643	0.0022	CcSEcCtD
Gefitinib—Urethral disorder—Vincristine—lymphatic system cancer	0.00064	0.00219	CcSEcCtD
Gefitinib—Eye disorder—Carmustine—lymphatic system cancer	0.000639	0.00219	CcSEcCtD
Gefitinib—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000639	0.00219	CcSEcCtD
Gefitinib—Hypersensitivity—Teniposide—lymphatic system cancer	0.000637	0.00218	CcSEcCtD
Gefitinib—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000636	0.00218	CcSEcCtD
Gefitinib—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000636	0.00218	CcSEcCtD
Gefitinib—Anaemia—Bleomycin—lymphatic system cancer	0.000631	0.00216	CcSEcCtD
Gefitinib—Asthenia—Teniposide—lymphatic system cancer	0.00062	0.00212	CcSEcCtD
Gefitinib—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.000617	0.00211	CcSEcCtD
Gefitinib—Melaena—Methotrexate—lymphatic system cancer	0.000617	0.00211	CcSEcCtD
Gefitinib—Malaise—Bleomycin—lymphatic system cancer	0.000615	0.00211	CcSEcCtD
Gefitinib—Pruritus—Teniposide—lymphatic system cancer	0.000611	0.00209	CcSEcCtD
Gefitinib—Arrhythmia—Carmustine—lymphatic system cancer	0.000611	0.00209	CcSEcCtD
Gefitinib—Cystitis—Methotrexate—lymphatic system cancer	0.000609	0.00208	CcSEcCtD
Gefitinib—Cardiac disorder—Vincristine—lymphatic system cancer	0.000606	0.00207	CcSEcCtD
Gefitinib—Alopecia—Carmustine—lymphatic system cancer	0.000605	0.00207	CcSEcCtD
Gefitinib—Body temperature increased—Fludarabine—lymphatic system cancer	0.0006	0.00205	CcSEcCtD
Gefitinib—Malnutrition—Carmustine—lymphatic system cancer	0.000596	0.00204	CcSEcCtD
Gefitinib—Cough—Bleomycin—lymphatic system cancer	0.000595	0.00204	CcSEcCtD
Gefitinib—Angiopathy—Vincristine—lymphatic system cancer	0.000593	0.00203	CcSEcCtD
Gefitinib—Diarrhoea—Teniposide—lymphatic system cancer	0.000591	0.00202	CcSEcCtD
Gefitinib—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000589	0.00201	CcSEcCtD
Gefitinib—Alopecia—Vincristine—lymphatic system cancer	0.000577	0.00197	CcSEcCtD
Gefitinib—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000571	0.00195	CcSEcCtD
Gefitinib—Bladder pain—Methotrexate—lymphatic system cancer	0.000571	0.00195	CcSEcCtD
Gefitinib—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000568	0.00194	CcSEcCtD
Gefitinib—Alopecia—Mitoxantrone—lymphatic system cancer	0.000562	0.00192	CcSEcCtD
Gefitinib—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00056	0.00191	CcSEcCtD
Gefitinib—Infection—Bleomycin—lymphatic system cancer	0.000553	0.00189	CcSEcCtD
Gefitinib—Anaemia—Carmustine—lymphatic system cancer	0.000551	0.00188	CcSEcCtD
Gefitinib—Vomiting—Teniposide—lymphatic system cancer	0.00055	0.00188	CcSEcCtD
Gefitinib—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000545	0.00187	CcSEcCtD
Gefitinib—Asthenia—Fludarabine—lymphatic system cancer	0.000545	0.00186	CcSEcCtD
Gefitinib—Rash—Teniposide—lymphatic system cancer	0.000545	0.00186	CcSEcCtD
Gefitinib—Dermatitis—Teniposide—lymphatic system cancer	0.000544	0.00186	CcSEcCtD
Gefitinib—Pruritus—Fludarabine—lymphatic system cancer	0.000537	0.00184	CcSEcCtD
Gefitinib—Anorexia—Bleomycin—lymphatic system cancer	0.000531	0.00182	CcSEcCtD
Gefitinib—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000529	0.00181	CcSEcCtD
Gefitinib—Anaemia—Vincristine—lymphatic system cancer	0.000526	0.0018	CcSEcCtD
Gefitinib—Hypotension—Bleomycin—lymphatic system cancer	0.00052	0.00178	CcSEcCtD
Gefitinib—Diarrhoea—Fludarabine—lymphatic system cancer	0.00052	0.00178	CcSEcCtD
Gefitinib—Nausea—Teniposide—lymphatic system cancer	0.000513	0.00176	CcSEcCtD
Gefitinib—Anaemia—Mitoxantrone—lymphatic system cancer	0.000512	0.00175	CcSEcCtD
Gefitinib—Hepatic failure—Methotrexate—lymphatic system cancer	0.00051	0.00174	CcSEcCtD
Gefitinib—Malaise—Mitoxantrone—lymphatic system cancer	0.000499	0.00171	CcSEcCtD
Gefitinib—Dyspnoea—Bleomycin—lymphatic system cancer	0.000497	0.0017	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000486	0.00166	CcSEcCtD
Gefitinib—Decreased appetite—Bleomycin—lymphatic system cancer	0.000484	0.00166	CcSEcCtD
Gefitinib—Cough—Mitoxantrone—lymphatic system cancer	0.000483	0.00165	CcSEcCtD
Gefitinib—Infection—Carmustine—lymphatic system cancer	0.000483	0.00165	CcSEcCtD
Gefitinib—Vomiting—Fludarabine—lymphatic system cancer	0.000483	0.00165	CcSEcCtD
Gefitinib—Rash—Fludarabine—lymphatic system cancer	0.000479	0.00164	CcSEcCtD
Gefitinib—Dermatitis—Fludarabine—lymphatic system cancer	0.000479	0.00164	CcSEcCtD
Gefitinib—Pain—Bleomycin—lymphatic system cancer	0.000476	0.00163	CcSEcCtD
Gefitinib—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000476	0.00163	CcSEcCtD
Gefitinib—Anorexia—Carmustine—lymphatic system cancer	0.000463	0.00159	CcSEcCtD
Gefitinib—Infection—Vincristine—lymphatic system cancer	0.000461	0.00158	CcSEcCtD
Gefitinib—Nervous system disorder—Vincristine—lymphatic system cancer	0.000455	0.00156	CcSEcCtD
Gefitinib—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000454	0.00155	CcSEcCtD
Gefitinib—Hypotension—Carmustine—lymphatic system cancer	0.000454	0.00155	CcSEcCtD
Gefitinib—Nausea—Fludarabine—lymphatic system cancer	0.000451	0.00154	CcSEcCtD
Gefitinib—Infection—Mitoxantrone—lymphatic system cancer	0.000449	0.00154	CcSEcCtD
Gefitinib—Shock—Mitoxantrone—lymphatic system cancer	0.000445	0.00152	CcSEcCtD
Gefitinib—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000443	0.00151	CcSEcCtD
Gefitinib—Urticaria—Bleomycin—lymphatic system cancer	0.000442	0.00151	CcSEcCtD
Gefitinib—Anorexia—Vincristine—lymphatic system cancer	0.000442	0.00151	CcSEcCtD
Gefitinib—Body temperature increased—Bleomycin—lymphatic system cancer	0.00044	0.00151	CcSEcCtD
Gefitinib—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000439	0.0015	CcSEcCtD
Gefitinib—Hypotension—Vincristine—lymphatic system cancer	0.000434	0.00148	CcSEcCtD
Gefitinib—Dyspnoea—Carmustine—lymphatic system cancer	0.000433	0.00148	CcSEcCtD
Gefitinib—Anorexia—Mitoxantrone—lymphatic system cancer	0.000431	0.00147	CcSEcCtD
Gefitinib—Decreased appetite—Carmustine—lymphatic system cancer	0.000423	0.00145	CcSEcCtD
Gefitinib—Hypotension—Mitoxantrone—lymphatic system cancer	0.000422	0.00144	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00042	0.00144	CcSEcCtD
Gefitinib—Pain—Carmustine—lymphatic system cancer	0.000416	0.00142	CcSEcCtD
Gefitinib—Constipation—Carmustine—lymphatic system cancer	0.000416	0.00142	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000413	0.00141	CcSEcCtD
Gefitinib—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00041	0.0014	CcSEcCtD
Gefitinib—Decreased appetite—Vincristine—lymphatic system cancer	0.000403	0.00138	CcSEcCtD
Gefitinib—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000403	0.00138	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000401	0.00137	CcSEcCtD
Gefitinib—Fatigue—Vincristine—lymphatic system cancer	0.0004	0.00137	CcSEcCtD
Gefitinib—Asthenia—Bleomycin—lymphatic system cancer	0.0004	0.00137	CcSEcCtD
Gefitinib—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000398	0.00136	CcSEcCtD
Gefitinib—Pain—Vincristine—lymphatic system cancer	0.000397	0.00136	CcSEcCtD
Gefitinib—Constipation—Vincristine—lymphatic system cancer	0.000397	0.00136	CcSEcCtD
Gefitinib—Pruritus—Bleomycin—lymphatic system cancer	0.000394	0.00135	CcSEcCtD
Gefitinib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000393	0.00134	CcSEcCtD
Gefitinib—Fatigue—Mitoxantrone—lymphatic system cancer	0.00039	0.00133	CcSEcCtD
Gefitinib—Pancreatitis—Methotrexate—lymphatic system cancer	0.000388	0.00133	CcSEcCtD
Gefitinib—Constipation—Mitoxantrone—lymphatic system cancer	0.000386	0.00132	CcSEcCtD
Gefitinib—Pain—Mitoxantrone—lymphatic system cancer	0.000386	0.00132	CcSEcCtD
Gefitinib—Body temperature increased—Carmustine—lymphatic system cancer	0.000384	0.00131	CcSEcCtD
Gefitinib—Abdominal pain—Carmustine—lymphatic system cancer	0.000384	0.00131	CcSEcCtD
Gefitinib—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000379	0.0013	CcSEcCtD
Gefitinib—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00037	0.00126	CcSEcCtD
Gefitinib—Abdominal pain—Vincristine—lymphatic system cancer	0.000367	0.00125	CcSEcCtD
Gefitinib—Body temperature increased—Vincristine—lymphatic system cancer	0.000367	0.00125	CcSEcCtD
Gefitinib—Urticaria—Mitoxantrone—lymphatic system cancer	0.000359	0.00123	CcSEcCtD
Gefitinib—Hypersensitivity—Carmustine—lymphatic system cancer	0.000358	0.00123	CcSEcCtD
Gefitinib—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000357	0.00122	CcSEcCtD
Gefitinib—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000357	0.00122	CcSEcCtD
Gefitinib—Pneumonia—Methotrexate—lymphatic system cancer	0.000355	0.00121	CcSEcCtD
Gefitinib—Vomiting—Bleomycin—lymphatic system cancer	0.000354	0.00121	CcSEcCtD
Gefitinib—Infestation—Methotrexate—lymphatic system cancer	0.000353	0.00121	CcSEcCtD
Gefitinib—Infestation NOS—Methotrexate—lymphatic system cancer	0.000353	0.00121	CcSEcCtD
Gefitinib—Rash—Bleomycin—lymphatic system cancer	0.000351	0.0012	CcSEcCtD
Gefitinib—Dermatitis—Bleomycin—lymphatic system cancer	0.000351	0.0012	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00035	0.0012	CcSEcCtD
Gefitinib—Asthenia—Carmustine—lymphatic system cancer	0.000349	0.00119	CcSEcCtD
Gefitinib—Stomatitis—Methotrexate—lymphatic system cancer	0.000344	0.00118	CcSEcCtD
Gefitinib—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000343	0.00117	CcSEcCtD
Gefitinib—Hypersensitivity—Vincristine—lymphatic system cancer	0.000342	0.00117	CcSEcCtD
Gefitinib—Haematuria—Methotrexate—lymphatic system cancer	0.000337	0.00115	CcSEcCtD
Gefitinib—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000334	0.00114	CcSEcCtD
Gefitinib—Epistaxis—Methotrexate—lymphatic system cancer	0.000333	0.00114	CcSEcCtD
Gefitinib—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000333	0.00114	CcSEcCtD
Gefitinib—Asthenia—Vincristine—lymphatic system cancer	0.000333	0.00114	CcSEcCtD
Gefitinib—Diarrhoea—Carmustine—lymphatic system cancer	0.000333	0.00114	CcSEcCtD
Gefitinib—Nausea—Bleomycin—lymphatic system cancer	0.000331	0.00113	CcSEcCtD
Gefitinib—Asthenia—Mitoxantrone—lymphatic system cancer	0.000324	0.00111	CcSEcCtD
Gefitinib—Haemoglobin—Methotrexate—lymphatic system cancer	0.000319	0.00109	CcSEcCtD
Gefitinib—Diarrhoea—Vincristine—lymphatic system cancer	0.000318	0.00109	CcSEcCtD
Gefitinib—Hepatitis—Methotrexate—lymphatic system cancer	0.000317	0.00108	CcSEcCtD
Gefitinib—Haemorrhage—Methotrexate—lymphatic system cancer	0.000317	0.00108	CcSEcCtD
Gefitinib—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000313	0.00107	CcSEcCtD
Gefitinib—Urethral disorder—Methotrexate—lymphatic system cancer	0.000311	0.00106	CcSEcCtD
Gefitinib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000309	0.00106	CcSEcCtD
Gefitinib—Vomiting—Carmustine—lymphatic system cancer	0.000309	0.00106	CcSEcCtD
Gefitinib—Rash—Carmustine—lymphatic system cancer	0.000307	0.00105	CcSEcCtD
Gefitinib—Dermatitis—Carmustine—lymphatic system cancer	0.000306	0.00105	CcSEcCtD
Gefitinib—Erythema multiforme—Methotrexate—lymphatic system cancer	0.0003	0.00103	CcSEcCtD
Gefitinib—Eye disorder—Methotrexate—lymphatic system cancer	0.000296	0.00101	CcSEcCtD
Gefitinib—Vomiting—Vincristine—lymphatic system cancer	0.000295	0.00101	CcSEcCtD
Gefitinib—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000294	0.00101	CcSEcCtD
Gefitinib—Rash—Vincristine—lymphatic system cancer	0.000293	0.001	CcSEcCtD
Gefitinib—Dermatitis—Vincristine—lymphatic system cancer	0.000292	0.001	CcSEcCtD
Gefitinib—Nausea—Carmustine—lymphatic system cancer	0.000289	0.000988	CcSEcCtD
Gefitinib—Angiopathy—Methotrexate—lymphatic system cancer	0.000288	0.000984	CcSEcCtD
Gefitinib—Vomiting—Mitoxantrone—lymphatic system cancer	0.000287	0.000983	CcSEcCtD
Gefitinib—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000286	0.000977	CcSEcCtD
Gefitinib—Rash—Mitoxantrone—lymphatic system cancer	0.000285	0.000975	CcSEcCtD
Gefitinib—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000285	0.000974	CcSEcCtD
Gefitinib—Alopecia—Methotrexate—lymphatic system cancer	0.00028	0.000958	CcSEcCtD
Gefitinib—Malnutrition—Methotrexate—lymphatic system cancer	0.000276	0.000944	CcSEcCtD
Gefitinib—Nausea—Vincristine—lymphatic system cancer	0.000276	0.000943	CcSEcCtD
Gefitinib—Nausea—Mitoxantrone—lymphatic system cancer	0.000268	0.000918	CcSEcCtD
Gefitinib—Anaemia—Methotrexate—lymphatic system cancer	0.000255	0.000872	CcSEcCtD
Gefitinib—Malaise—Methotrexate—lymphatic system cancer	0.000249	0.000851	CcSEcCtD
Gefitinib—Cough—Methotrexate—lymphatic system cancer	0.000241	0.000824	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000233	0.000798	CcSEcCtD
Gefitinib—Infection—Methotrexate—lymphatic system cancer	0.000224	0.000765	CcSEcCtD
Gefitinib—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000221	0.000755	CcSEcCtD
Gefitinib—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00022	0.000754	CcSEcCtD
Gefitinib—Skin disorder—Methotrexate—lymphatic system cancer	0.000219	0.000748	CcSEcCtD
Gefitinib—Anorexia—Methotrexate—lymphatic system cancer	0.000215	0.000734	CcSEcCtD
Gefitinib—Hypotension—Methotrexate—lymphatic system cancer	0.00021	0.00072	CcSEcCtD
Gefitinib—Dyspnoea—Methotrexate—lymphatic system cancer	0.000201	0.000687	CcSEcCtD
Gefitinib—Decreased appetite—Methotrexate—lymphatic system cancer	0.000196	0.00067	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000194	0.000665	CcSEcCtD
Gefitinib—Fatigue—Methotrexate—lymphatic system cancer	0.000194	0.000664	CcSEcCtD
Gefitinib—Pain—Methotrexate—lymphatic system cancer	0.000193	0.000659	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000184	0.00063	CcSEcCtD
Gefitinib—Urticaria—Methotrexate—lymphatic system cancer	0.000179	0.000612	CcSEcCtD
Gefitinib—Body temperature increased—Methotrexate—lymphatic system cancer	0.000178	0.000609	CcSEcCtD
Gefitinib—Abdominal pain—Methotrexate—lymphatic system cancer	0.000178	0.000609	CcSEcCtD
Gefitinib—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000166	0.000568	CcSEcCtD
Gefitinib—Asthenia—Methotrexate—lymphatic system cancer	0.000162	0.000553	CcSEcCtD
Gefitinib—Pruritus—Methotrexate—lymphatic system cancer	0.000159	0.000545	CcSEcCtD
Gefitinib—Diarrhoea—Methotrexate—lymphatic system cancer	0.000154	0.000527	CcSEcCtD
Gefitinib—Vomiting—Methotrexate—lymphatic system cancer	0.000143	0.00049	CcSEcCtD
Gefitinib—Rash—Methotrexate—lymphatic system cancer	0.000142	0.000486	CcSEcCtD
Gefitinib—Dermatitis—Methotrexate—lymphatic system cancer	0.000142	0.000485	CcSEcCtD
Gefitinib—Nausea—Methotrexate—lymphatic system cancer	0.000134	0.000458	CcSEcCtD
